Author

Torres F

Universitat Aut

Biography

Dr. Torres F is working in Paediatrics Unit, Hospital del Mar, Barcelona, Spain, FEDER, Instituto de Salud Carlos III, Madrid, Spain. His international experience includes various programs, contributions and participation in different countries for diverse fields of study. His research interests reflect in his wide range of publications in various national and international journals and major research interests are Paediatrics, Paediatric Cardiology, Cardiac surgery, Cardiac Function.
Title
Cited by
Year
Effect of intra-arterial alteplase vs placebo following successful thrombectomy on functional outcomes in patients with large vessel occlusion acute ischemic stroke: the CHOICE …
A Renú, M Millán, L San Román, J Blasco, J Martí-Fàbregas, M Terceño, ...Jama 327 (9), 826-835, 2022202
100
2022
A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia
C Avendaño-Solá, A Ramos-Martínez, E Muñez-Rubio, B Ruiz-Antorán, ...The Journal of Clinical Investigation 131 (20), 2021202
79
2021
Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression
LA Orci, M Sanduzzi-Zamparelli, B Caballol, V Sapena, N Colucci, ...Clinical Gastroenterology and Hepatology 20 (2), 283-292. e10, 2022202
74
2022
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis
V Sapena, M Enea, F Torres, C Celsa, J Rios, GEM Rizzo, P Nahon, ...Gut 71 (3), 593-604, 2022202
54
2022
Clinical and genetic features of autosomal dominant Alport syndrome: a cohort study
M Furlano, V Martínez, M Pybus, Y Arce, J Crespí, M del Prado Venegas, ...American Journal of Kidney Diseases 78 (4), 560-570. e1, 2021202
41
2021
Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis
C Villanueva, A Albillos, J Genescà, JC Garcia-Pagan, A Brujats, ...Journal of hepatology 75 (3), 589-599, 2021202
39
2021
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis
C Villanueva, F Torres, SK Sarin, HA Shah, D Tripathi, A Brujats, ...Journal of hepatology 77 (4), 1014-1025, 2022202
30
2022
First-line immune checkpoint inhibitor-based sequential therapies for advanced hepatocellular carcinoma: rationale for future trials
G Cabibbo, M Reig, C Celsa, F Torres, S Battaglia, M Enea, GEM Rizzo, ...Liver Cancer 11 (1), 75-84, 2022202
21
2022
Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis
A Juanola, I Graupera, C Elia, S Piano, C Solé, M Carol, M Pérez-Guasch, ...Journal of hepatology 76 (1), 107-114, 2022202
12
2022
Patients undergoing bariatric surgery: a special risk group for lifestyle, emotional and behavioral adaptations during the COVID-19 lockdown. Lessons from the first wave
A Andreu, L Flores, J Molero, C Mestre, A Obach, F Torres, V Moizé, ...Obesity Surgery, 1-9, 2022202
12
2022
Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life
M Carol, M Pérez-Guasch, E Solà, M Cervera, S Martínez, A Juanola, ...PloS one 17 (4), e0265153, 2022202
11
2022
p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis
L Solé, T Lobo-Jarne, D Álvarez-Villanueva, J Alonso-Marañón, Y Guillén, ...Nature communications 13 (1), 2866, 2022202
10
2022
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules
M Sanduzzi-Zamparelli, Z Mariño, S Lens, V Sapena, G Iserte, A Pla, ...Journal of hepatology 76 (4), 74-2, 2022202
8
2022
Risk of non‐tumoural portal vein thrombosis in patients with HCV‐induced cirrhosis after sustained virological response
M Mandorfer, F Turon, S Lens, A Baiges, Á García‐Criado, A Darnell, ...Liver International 41 (12), 2954-294, 2021202
6
2021
Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label …
E Diago-Sempere, JL Bueno, A Sancho-López, EM Rubio, F Torres, ...Trials 22, 1-14, 2021202
5
2021
Predictive models for forecasting public health scenarios: practical experiences applied during the first wave of the COVID-19 pandemic
JM Martin-Moreno, A Alegre-Martinez, V Martin-Gorgojo, ...International Journal of Environmental Research and Public Health 19 (9), 556, 2022202
4
2022
Stratified efficacy of first-line therapy to prevent first variceal bleeding according to previous decompensation of cirrhosis. A competing-risk meta-analyses of individual …
C Villanueva, V Sapena, GH Lo, YS Seo, HA Shah, V Singh, D Tripathi, ...Journal of Hepatology, S625-S626, 2022202
3
2022
Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease
J Naranjo, M Furlano, F Torres, J Hernandez, M Pybus, L Ejarque, ...Clinical Kidney Journal 15 (5), 91-91, 0
2
2022
Increased circulating levels of growth differentiation factor 15 in association with metabolic disorders in people living with HIV receiving combined antiretroviral therapy
P Domingo, MG Mateo, J Villarroya, R Cereijo, F Torres, JC Domingo, ...Journal of clinical medicine 11 (3), 549, 0
2
2022
The probability of receiving a kidney transplantation in end-stage kidney disease patients who are treated with haemodiafiltration or haemodialysis: a pooled individual …
RWM Vernooij, W Law, SAE Peters, B Canaud, A Davenport, ...BMC nephrology (1), 1-9, 010
2
2021

Referred From: https://scholar.google.com/citations?user=4PejNjIAAAAJ&hl=en&oi=sra

Cited by
Citations 20603
h-index 70
i10-index 194
Recommended Journals
Open Access Journals